《半日總結》恆指升168點 醫藥股彈 中生製藥漲逾8%
亞太區早市普遍反彈,港股早市上升。恆指高開115點,其後升幅曾擴大至298點見17,342點,半日升168點或1%,報17,213點;國指升54點或0.9%,報5,913點;恆生科技指數升50點或1.4%,報3,762點。大市半日成交總額424.68億元,滬、深港通南下交易半日淨流入13.99億及7.17億元人民幣。
醫藥股反彈,石藥(01093.HK)、中生製藥(01177.HK)及翰森(03692.HK)升7.3%、8.3%及7.8%,藥明生物(02269.HK)及信達生物(01801.HK)升4.4%及3.7%。摩通指全球醫療科技公司如雅培(ABT.US)、強生(JNJ.US)等公司第三季旗下中國收入頗為可觀,相關公司認為中國第三季醫療行業反貪腐運動並未導致程序量有重大變化,並指帶量採購(VBP)對中國業務的影響是可控的,可以透過新產品的推出或降價帶來的銷售增加來抵銷。
內房股合景泰富(01813.HK)及恆大(03333.HK)升7.1%及5.4%,新城(01030.HK)及碧桂園(02007.HK)升4%及2.9%。物管股華潤萬象(01209.HK)及碧服(06098.HK)升3.9%及3%。潤地(01109.HK)擬分拆基礎設施REIT於深交所上市,股價升1.4%。
內銀股建行(00939.HK)首三季多賺3.1%,股價平收報4.53元。農行(01288.HK)及工行(01398.HK)升1.4%及1.3%。內險股國壽(02628.HK)第三季淨利潤跌99%,半日股價跌2.6%報10.46元。中國太平(00966.HK)及眾安在線(06060.HK)跌逾2%,中國平安(02318.HK)跌1.4%。其他金融股方面,匯控(00005.HK)反彈1.5%報57.95元,港交所(00388.HK)及友邦(01299.HK)升0.3%及0.1%。渣打(02888.HK)昨午公布季績後股價挫逾一成,今日半日反彈1.3%,恆生(00011.HK)升1.5%。
內地10月共批87款國產網絡遊戲,網易(09999.HK)遊戲《射雕》在列。網易升2.9%報168.4元。其餘科技股方面,阿里(09988.HK)升2.3%報81.55元,騰訊(00700.HK)升0.8%報290元,京東(09618.HK)升3.1%報101.1元。小米(01810.HK)平收報13.36元,美團(03690.HK)升1.2%。東方甄選(01797.HK)及晶片股中芯(00981.HK)升4.3%及4.9%,京東健康(06618.HK)升3.6%。
大家樂(00341.HK)早市炒高8.3%。龍源(00916.HK)首九月多賺19%,半日股價升7.6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.